Fingerprint
Dive into the research topics where Clemens Mellink is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Fixed-duration ibrutinib–venetoclax with MRD-guided ibrutinib–obinutuzumab intensification in first-line chronic lymphocytic leukaemia (HOVON 158/NEXT STEP): primary analysis of a multicentre, open-label, phase 2 trial
Kater, A. P., Kersting, S., Dubois, J. M., van der Holt, B., da Cunha-Bang, C., te Raa, D., Idink, C., de Boer, F., Droogendijk, J., de Heer, K., van der Burg, L., Nijziel, M. R., Tick, L., Levenga, H., Silbermann, M., Ludwig, I., Beeker, A., Bellido, M., Dobber, J. A. & Evers, L. M. & 9 others, , 1 Dec 2025, In: The Lancet Haematology. 12, 12, p. e935-e945Research output: Contribution to journal › Article › Academic › peer-review
-
Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial
Niemann, C. U., Dubois, J., Nasserinejad, K., da Cunha-Bang, C., Kersting, S., Enggaard, L., Veldhuis, G. J., Mous, R., Mellink, C. H. M., van der Kevie-Kersemaekers, A.-M. F., Dobber, J. A., Poulsen, C. B., Razawy, W., Hollestein, R., Frederiksen, H., Janssens, A., Schjødt, I., Dompeling, E. C., Ranti, J. & Brieghel, C. & 5 others, , 12 Aug 2025, In: Blood. 9, 15, p. 3665-3675 11 p.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile27 Downloads (Pure) -
The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL
Kater, A. P., Harrup, R., Kipps, T. J., Eichhorst, B., Owen, C. J., Assouline, S., Lamanna, N., Robak, T., de la Serna, J., Jaeger, U., Cartron, G., Montillo, M., Mellink, C., Langerak, A. W., Chyla, B., Popovic, R., Jiang, Y., Millen, R., Lefebure, M. & Thadani-Mulero, M. & 2 others, , 5 Jun 2025, In: Blood. 145, 23, p. 2733-2745 13 p.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile55 Downloads (Pure) -
Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial
Kater, A. P., Arslan, Ö., Demirkan, F., Herishanu, Y., Ferhanoglu, B., Diaz, M. G., Leber, B., Montillo, M., Panayiotidis, P., Rossi, D., Skarbnik, A., Tempescul, A., Turgut, M., Mellink, C. H., van der Kevie-Kersemaekers, A.-M. F., Lanham, S., Sale, B., del Rio, L., Popovic, R. & Chyla, B. J. & 7 others, , 1 Apr 2024, In: The Lancet Oncology. 25, 4, p. 463-473 11 p.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile40 Downloads (Pure) -
Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL
HOVON CLL Working Group, 28 Sept 2023, In: Blood. 142, 13, p. 1131-1142 12 p.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile28 Downloads (Pure)